Once-Weekly Insulin Icodec Versus Once-Daily Insulin Degludec in Insulin-Naive Chinese Participants with Type 2 Diabetes: A Post Hoc Analysis of ONWARDS 3.

• Tác giả: Soumitra Kar, Congcong Li, Yijun Li, Ming Liu, Zijian Luan, Yiming Mu, Guoyue Yuan, Xing Zhong
• Ngôn ngữ: eng
• Ký hiệu phân loại: 617.057 Endoscopic surgery
• Thông tin xuất bản: United States : Diabetes therapy : research, treatment and education of diabetes and related disorders , 2025
• Bộ sưu tập: NCBI
• ID: 722460

Tóm tắt

 INTRODUCTION: This post hoc analysis evaluated subgroup data from China (Chinese mainland, n = 100
  Taiwan, n = 45) in ONWARDS 3, a 26-week, randomized, double-blind, double-dummy, treat-to-target, phase 3a trial comparing the efficacy and safety of once-weekly insulin icodec (icodec) versus once-daily insulin degludec (degludec) in insulin-naive participants with type 2 diabetes (T2D). METHODS: Adults were randomized 1:1 to icodec and once-daily placebo (icodec
  n = 72) or degludec and once-weekly placebo (degludec
  n = 73). The primary endpoint was change in glycated hemoglobin (HbA RESULTS: At week 26, from baseline values of 8.22% (icodec) and 8.39% (degludec), estimated mean changes in HbA CONCLUSION: In insulin-naive Chinese individuals with T2D, once-weekly icodec treatment showed significantly greater HbA GOV IDENTIFIER: NCT04795531.